Lansoprazol Lanzogastro

Lansoprazole, the active ingredient in Lansoprazol Lanzogastro, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders in adult patients, and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive oesophagitis, peptic ulcer disease and Zollinger‑Ellison syndrome.

GNH USA supplies Lansoprazol Lanzogastro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable bulk shipments and adhering to stringent quality standards across all regulated markets.

Lansoprazole acts on the gastric acid secretion pathway and is used to treat several acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): reduces esophageal acid exposure and promotes symptom relief. - Erosive oesophagitis: facilitates healing of erosive lesions in the esophagus. - Peptic ulcer disease: supports ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Adverse reactions may occur with lansoprazole therapy. Most are mild and transient, but serious events are reported rarely.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued use. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the upper abdomen. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea with abdominal cramping. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Hepatic enzyme elevation: abnormal liver function tests. - Hypomagnesemia: low serum magnesium with prolonged use. - Acute pancreatitis: sudden abdominal pain with elevated enzymes.

Before initiating lansoprazole, consider the following safety measures.

- Assess renal function: adjust therapy in severe renal impairment. - Avoid concomitant use with strong CYP2C19 inhibitors: may increase drug exposure. - Monitor for Clostridioides difficile infection: especially in hospitalized patients. - Use with caution in the elderly: higher risk of bone fractures. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lansoprazole can interact with several medicines, altering their effectiveness or safety.

Major Interactions (Avoid): - Ketoconazole: reduced absorption of ketoconazole when taken together. - Atazanavir: decreased antiviral efficacy of atazanavir. - Clopidogrel: diminished antiplatelet effect of clopidogrel.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Phenytoin: reduced phenytoin plasma concentrations. - Digoxin: potential rise in serum digoxin levels.